Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab

Glioblastoma Multiforme (GBM) Clinical Trial

Official title:
Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab

Status Withdrawn

Clinical Trial Summary

This exploratory study uses [18F] Fluciclatide and Positron emission tomography (PET) imaging in patients with glioblastoma multiforme (GBM) to be treated with Bevacizumab. The primary objective of this study is to determine the association of [18F] Fluciclatide uptake, fludeoxyglucose (FDG) uptake, and tumor blood flow/perfusion determined with H215O and Magnetic resonance imaging (MRI) and correlate these variables with time to progression (TTP) in participants with GBM treated with Bevacizumab.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01788280
Study type	Interventional
Source	University of Utah
Contact
Status	Withdrawn
Phase	Phase 2
Start date	January 2018
Completion date	January 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04587830` - ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme	Phase 1
Completed	`NCT01109095` - CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM	Phase 1
Active, not recruiting	`NCT04019002` - Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma	Phase 1
Terminated	`NCT02654041` - Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients	Phase 2
Recruiting	`NCT03213002` - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM	Phase 1/Phase 2
Completed	`NCT01238237` - Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA	Phase 1
Completed	`NCT02202993` - TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM	Phase 1